Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance Schmidt S; Rainer J; Ploner C; Presul E; Riml S; Kofler RCell Death Differ 2004[Jul]; 11 Suppl 1 (ä): S45-55The ability of glucocorticoids (GC) to efficiently kill lymphoid cells has led to their inclusion in essentially all chemotherapy protocols for lymphoid malignancies. This review summarizes recent findings related to the molecular basis of GC-induced apoptosis and GC resistance, and discusses their potential clinical implications. Accumulating evidence suggests that GC may induce cell death via different pathways resulting in apoptotic or necrotic morphologies, depending on the availability/responsiveness of the apoptotic machinery. The former might result from regulation of typical apoptosis genes such as members of the Bcl-2 family, the latter from detrimental GC effects on essential cellular functions possibly perpetuated by GC receptor (GR) autoinduction. Although other possibilities exist, GC resistance might frequently result from defective GR expression, perhaps the most efficient means to target multiple antileukemic GC effects. Numerous novel drug combinations are currently being tested to prevent resistance and improve GC efficacy in the therapy of lymphoid malignancies.|Animals[MESH]|Apoptosis/drug effects/genetics/*physiology[MESH]|Cell Death/genetics/physiology[MESH]|Drug Resistance, Neoplasm/genetics[MESH]|Gene Expression[MESH]|Glucocorticoids/metabolism/*physiology/therapeutic use[MESH]|Humans[MESH]|Leukemia, Lymphoid/drug therapy/genetics[MESH]|Mice[MESH]|Models, Biological[MESH]|Mutation[MESH]|Protein Isoforms/genetics/physiology[MESH]|Proto-Oncogene Proteins c-bcl-2/genetics/physiology[MESH]|Receptors, Glucocorticoid/genetics/physiology[MESH]|Transcriptional Activation/genetics/physiology[MESH] |
